@article{d4f1131c432d4f20bff04f2e5a64f2f8,
title = "Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial",
abstract = "This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.",
keywords = "Adolescent, Anti-TNF, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Rheumatoid, Certolizumab Pegol, DMARDs (biologic), Disease Activity, Double-Blind Method, Drug Therapy, Combination, Immunoglobulin Fab Fragments, Immunosuppressive Agents, Maintenance Chemotherapy, Methotrexate, Middle Aged, Polyethylene Glycols, Remission Induction, Rheumatoid Arthritis, Severity of Illness Index, Treatment Outcome, Young Adult, Adolescent, Anti-TNF, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Rheumatoid, Certolizumab Pegol, DMARDs (biologic), Disease Activity, Double-Blind Method, Drug Therapy, Combination, Immunoglobulin Fab Fragments, Immunosuppressive Agents, Maintenance Chemotherapy, Methotrexate, Middle Aged, Polyethylene Glycols, Remission Induction, Rheumatoid Arthritis, Severity of Illness Index, Treatment Outcome, Young Adult",
author = "Gianfranco Ferraccioli and Smolen, {J. S.} and P. Emery and W. Samborski and F. Berenbaum and Davies, {O. R.} and W. Koetse and O. Purcaru and B. Bennett and H. Burkhardt",
year = "2015",
doi = "10.1136/annrheumdis-2013-204632",
language = "English",
volume = "74",
pages = "843--850",
journal = "ANNALS OF THE RHEUMATIC DISEASES",
issn = "0003-4967",
publisher = "London, United Kingdom: BMJ / British Medical Journal Publishing Group",
}